In the NILE Study, the Guardant360® test results showed more than 90% agreement with tissue for targetable genomic alterations. Actionable tumor mutations missed during tissue biopsies can be detected by our comprehensive liquid biopsy. Click on the video to find out more.

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360. Guardant360®.

Test. Take Action.